Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites

Exclusion Criteria

• •Non-malignant ascites (e.g., portal hypertension ascites or infected ascites);
• •Presence of contraindications to immunotherapy (including long-term hormone use, history of radiation pneumonitis, radiation hepatitis, radiation enteritis, etc.);
• •Combination of other serious cardiopulmonary diseases that affect the treatment, etc;
• •Patients with extensive abdominal adhesions; encapsulated peritoneal fluid; history of intestinal obstruction; and malignant patients with extensive distant metastases in the terminal stage;
• •Women who are breastfeeding, pregnant, or preparing for pregnancy;
• •Patients with plasma albumin (ALB) \<30 g/L and severe hypoproteinemia;
• •Patients with known hypersensitivity to components of the test drug or its analogues;
• •Patients with other severe, acute or chronic diseases that may interfere with the interpretation of the study results and who, in the judgement of the investigator, are unsuitable for participation in the clinical trial;
• •Patients with cognitive dysfunction, or poor treatment compliance as judged by the investigator;
• •Participants in other clinical trials within 4 weeks;
• •Combination of other malignancies;
• •Those who, in the opinion of the investigator, are not suitable for participation in the clinical trial.